'Objective response' presentation slideshows

Immunotherapy for Prostate Cancer: Are we on the right target?

Immunotherapy for Prostate Cancer: Are we on the right target? . Susan F. Slovin, MD, PhD Sidney Kimmel Center for Prostate and Urologic Cancers Memorial Sloan-Kettering Cancer Center New York, New York. Rationale for Vaccines in Prostate Cancer.

388 views • 38 slides

Gemcitabine combined with radiation therapy in patients with locally advanced unresectable pancreatic cancer

Gemcitabine combined with radiation therapy in patients with locally advanced unresectable pancreatic cancer. Ron Epelbaum,M.D. Department of Oncology Rambam Medical Center Haifa, Israel January 2001. Locally advanced unresectable pancreatic cancer. Background Definitions and statistics

576 views • 32 slides

KRAS Status in Response to Cetuximab

358 views • 30 slides

S. Pignata 1 , G. Scambia 2 , A. Savarese 3 , R. Sorio 4 , E. Breda 5 ,

Carboplatin plus Paclitaxel versus Carboplatin plus Stealth Liposomal Doxorubicin in patients with advanced ovarian cancer: activity and safety results of the MITO-2 randomized multicenter trial. S. Pignata 1 , G. Scambia 2 , A. Savarese 3 , R. Sorio 4 , E. Breda 5 ,

409 views • 24 slides

Background

Bevacizumab plus Interferon-alpha versus Interferon-alpha Monotherapy in Patients with Metastatic Renal Cell Carcinoma: Results of Overall Survival for CALGB 90206.

315 views • 18 slides

Goal- palliation and symptom control Objective response rates are low

Measuring the benefit of palliative chemotherapy in women with platinum refractory/ resistant ovarian cancer. Michael Friedlander Phyllis Butow, Martin Stockler, Corona Gainford, Julie Martyn, Amit Oza, Heidi Donovan, Brigitte Miller and Madeline King.

273 views • 17 slides

O.S. Nielsen, P. Reichardt, D. Pink, J. Lindegaard, S. Daugaard, C. Hermans, K. Stoichkov, M. van Glabbeke, I. Judson.

CTOS 11th Annual Meeting 2005 Boca Raton, Florida. Safety of Caelyx combined with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas. Final data of an EORTC phase I study. . O.S. Nielsen, P. Reichardt, D. Pink, J. Lindegaard,

279 views • 12 slides

HIV--Death and Dying

325 views • 12 slides

O.S. Nielsen, P. Reichardt, D. Pink, J. Lindegaard, S. Daugaard, C. Hermans, K. Stoichkov,

CTOS 11th Annual Meeting 2005 Boca Raton, Florida. Safety of Caelyx combined with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas. Final data of an EORTC phase I study. O.S. Nielsen, P. Reichardt, D. Pink, J. Lindegaard,

239 views • 12 slides